Please wait while we load the requested 10-Q report or click the link below:
FOR IMMEDIATE RELEASE
Director, Investor Relations, Corporate Strategy & Development
Glaukos Corporation Announces Second Quarter 2018 Financial Results
San Clemente, CA – August 2, 2018 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the second quarter ended June 30, 2018. Key highlights include:
“We are very pleased with the company’s continued solid execution through the second quarter, both in the U.S. and international markets, which allowed us to raise our 2018 revenue guidance,” said Thomas Burns, Glaukos president and chief executive officer. “In addition to achieving record quarterly revenue in the second quarter, we also accomplished a pivotal milestone with U.S. FDA approval of the iStent inject Trabecular Micro-Bypass System, our next-generation trabecular micro-bypass device. Trained surgeons have already successfully completed several initial iStent inject procedures and we are excited to commence full commercial launch activities later this month. iStent inject not only represents a compelling new treatment option for U.S. ophthalmic surgeons and their patients, but also further strengthens our leadership position in the growing Micro-Invasive Glaucoma Surgery market.”
Second Quarter 2018 Financial Results
Net sales rose 5% in the second quarter of 2018 to $43.2 million, compared to $41.3 million in the same period in 2017.
Gross margin for the second quarter of 2018 was approximately 86%, compared to approximately 87% in the same period in 2017.
Operating expenses for the second quarter of 2018 rose 4% to $41.2 million, compared to $39.6 million in the same period in 2017, which included a $5.3 million in-process R&D charge. The year-over-year increase reflected primarily growth in domestic sales, marketing and administrative personnel and expenses, the
The following information was filed by Glaukos Corp (GKOS) on Thursday, August 2, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Glaukos Corp's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Glaukos Corp.